AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation

Experimental Hematology

Volumn 36, Issue 11, 2008, Pages 1449-1460.e1

  Balkhi, Mumtaz Yaseen ^a   Christopeit, Maximilian ^a   Chen, Yong ^a   Geletu, Mulu ^a   Behre, Gerhard ^a  

^a State Center for Cell and Gene Therapy   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD34 ANTIGEN; EIGHT TWENTY ONE PROTEIN; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; SHORT HAIRPIN RNA; SURVIVIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA 1 GENE; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL NUCLEUS; CONTROLLED STUDY; DRUG MECHANISM; EIGHT TWENTY ONE GENE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC MODEL; GRANULOCYTE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR BIOLOGY; MYELOID LEUKEMIA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; QUANTITATIVE GENETICS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSCRIPTION REGULATION; TUMOR GENE; CYTOLOGY; GENETIC TRANSCRIPTION; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

BASE SEQUENCE; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GRANULOCYTES; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 53749095428     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.05.008     Document Type: Article

References (35)

1. Bitter M.A., Le Beau M.M., Rowley J.D., Larson R.A., Golomb H.M., and Vardiman J.W. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol 18 (1987) 211-225
2. Tighe J.E., and Calabi F. t(8;21) breakpoints are clustered between alternatively spliced exons of MTG8. Clin Sci (Lond) 89 (1995) 215-218
3. Erickson P., Gao J., Chang K.S., et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80 (1992) 1825-1831
4. Minucci S., Maccarana M., Cioce M., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 5 (2000) 811-820
5. Racanicchi S., Maccherani C., Liberatore C., et al. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. Embo J 24 (2005) 1232-1242
6. Ferrara F.F., Fazi F., Bianchini A., et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61 (2001) 2-7
7. Melnick A., Carlile G.W., McConnell M.J., Polinger A., Hiebert S.W., and Licht J.D. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood 96 (2000) 3939-3947
8. Chevallier N., Corcoran C.M., Lennon C., et al. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood 103 (2004) 1454-1463
9. Meyers S., Downing J.R., and Hiebert S.W. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13 (1993) 6336-6345
10. Meyers S., Lenny N., and Hiebert S.W. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 15 (1995) 1974-1982
11. Pabst T., Mueller B.U., Harakawa N., et al. AML1/ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7 (2001) 444-451
12. Zhang D.E., Hetherington C.J., Meyers S., et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 16 (1996) 1231-1240
13. Yergeau D.A., Hetherington C.J., Wang Q., et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1/ETO fusion gene. Nat Genet 15 (1997) 303-306
14. Hirohashi Y., Torigoe T., Maeda A., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8 (2002) 1731-1739
15. Rohayem J., Diestelkoetter P., Weigle B., et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 60 (2000) 1815-1817
16. Wagner M., Schmelz K., Wuchter C., Ludwig W.D., Dorken B., and Tamm I. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 119 (2006) 1291-1297
17. Fukuda S., and Pelus L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98 (2001) 2091-2100
18. Grignani F., Kinsella T., Mencarelli A., et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 58 (1998) 14-19
19. Li F., and Altieri D.C. Transcriptional analysis of human survivin gene expression. Biochem J 344 Pt 2 (1999) 305-311
20. Behre G., Smith L.T., and Tenen D.G. Use of a promoterless Renilla luciferase vector as an internal control plasmid for transient co-transfection assays of Ras-mediated transcription activation. Biotechniques 26 (1999) 24-26 28
21. Tanaka T., Tanaka K., Ogawa S., et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. Embo J 14 (1995) 341-350
22. Westendorf J.J., Yamamoto C.M., Lenny N., Downing J.R., Selsted M.E., and Hiebert S.W. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 18 (1998) 322-333
23. Erickson R.L., Hemati N., Ross S.E., and MacDougald O.A. p300 coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha. J Biol Chem 276 (2001) 16348-16355
24. Radomska H.S., Huettner C.S., Zhang P., Cheng T., Scadden D.T., and Tenen D.G. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18 (1998) 4301-4314
25. Balkhi M.Y., Trivedi A.K., Geletu M., et al. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene 25 (2006) 7041-7058
26. Smith L.T., Hohaus S., Gonzalez D.A., Dziennis S.E., and Tenen D.G. PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 88 (1996) 1234-1247
27. Legraverend C., Antonson P., Flodby P., and Xanthopoulos K.G. High level activity of the mouse CCAAT/enhancer binding protein (C/EBP alpha) gene promoter involves autoregulation and several ubiquitous transcription factors. Nucleic Acids Res 21 (1993) 1735-1742
28. Timchenko N., Wilson D.R., Taylor L.R., et al. Autoregulation of the human C/EBP alpha gene by stimulation of upstream stimulatory factor binding. Mol Cell Biol 15 (1995) 1192-1202
29. Geletu M., Balkhi M.Y., Peer Zada A.A., et al. Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9. Blood 110 (2007) 3301-3309
30. Kim J., Cantwell C.A., Johnson P.F., Pfarr C.M., and Williams S.C. Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation. J Biol Chem 277 (2002) 38037-38044
31. Tonks A., Pearn L., Tonks A.J., et al. The AML1/ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101 (2003) 624-632
32. Gurbuxani S., Xu Y., Keerthivasan G., Wickrema A., and Crispino J.D. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A 102 (2005) 11480-11485
33. Altieri D.C. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5 (2006) 478-482
34. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
35. Fukuda S., and Pelus L.M. Survivin a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5 (2006) 1087-1098